Shahar Zimand
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shahar Zimand has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
J Hegesh
2 shared publicationsM Frand
2 shared publicationsP Benjamin
2 shared publicationsAram K Smolinsky
1 shared publicationD Mishaly
1 shared publicationDavid Mishaly
1 shared publication
Latest Publications
- 1 April 2000
- Vol. 2 (4) , 316-7
Constrictive pericarditis presented by generalized edema (anasarca).
- 1 November 1999
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 68 (5) , 1869-1871
Left superior vena cava to the left atrium: do we have to change the traditional approach?
- 1 November 1999
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 68 (5) , 1869-1871
Left superior vena cava to the left atrium: do we have to change the traditional approach?
- 1 October 1998
- Vol. 135, 276-9, 335
[Transcatheter closure of atrial septal defects: initial clinical applications].
The incidence of congenital heart defects is 0.8% of liveborn infants. Of these 13% are ostium secundum atrial septal defects (ASD) which can be successfully repaired by open heart surgery with less than 1% mortality. However, morbidity associated with cardiac surgery is universal. Transcatheter closure of ASDs was introduced 2 decades ago to decrease surgical complications, hospital stay and cost. Few devices have undergone clinical trials but all of them have been associated with instances of failure and complications. The most important mechanism for acute failure was selection of cases with too large a defect or selection of a defective device. In the past decade great progress has been made with the aid of transesophageal echocardiography (TEE) and modifications of the device. We present our experience in our first 5 patients. They ranged in age from 4 to 27 years; the ASD diameter was 11-15 mm and the device diameter was 17-33 mm. All transcatheter closures were performed on the same day without any complications, and all patients were discharged home after 2 days of hospitalization. We conclude that transcatheter occlusion of ASDs up to 15 mm is feasible, relatively safe and effective. This transcatheter method appears to be a viable alternative to surgery for some patients with secundum atrial septal defects.
- 1 October 1998
- Vol. 135, 276-9, 335
[Transcatheter closure of atrial septal defects: initial clinical applications].
The incidence of congenital heart defects is 0.8% of liveborn infants. Of these 13% are ostium secundum atrial septal defects (ASD) which can be successfully repaired by open heart surgery with less than 1% mortality. However, morbidity associated with cardiac surgery is universal. Transcatheter closure of ASDs was introduced 2 decades ago to decrease surgical complications, hospital stay and cost. Few devices have undergone clinical trials but all of them have been associated with instances of failure and complications. The most important mechanism for acute failure was selection of cases with too large a defect or selection of a defective device. In the past decade great progress has been made with the aid of transesophageal echocardiography (TEE) and modifications of the device. We present our experience in our first 5 patients. They ranged in age from 4 to 27 years; the ASD diameter was 11-15 mm and the device diameter was 17-33 mm. All transcatheter closures were performed on the same day without any complications, and all patients were discharged home after 2 days of hospitalization. We conclude that transcatheter occlusion of ASDs up to 15 mm is feasible, relatively safe and effective. This transcatheter method appears to be a viable alternative to surgery for some patients with secundum atrial septal defects.